Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 64 | 2025 | 21206 | 2.790 |
Why?
|
Mastectomy | 26 | 2023 | 1861 | 2.410 |
Why?
|
Mastectomy, Segmental | 12 | 2024 | 974 | 1.580 |
Why?
|
Sentinel Lymph Node Biopsy | 14 | 2025 | 737 | 1.080 |
Why?
|
Axilla | 11 | 2024 | 623 | 1.080 |
Why?
|
Neoplasm Staging | 16 | 2024 | 11244 | 0.760 |
Why?
|
Mammaplasty | 8 | 2021 | 1268 | 0.710 |
Why?
|
Mastectomy, Modified Radical | 4 | 2023 | 62 | 0.680 |
Why?
|
Lymph Nodes | 6 | 2022 | 3474 | 0.660 |
Why?
|
Quality of Life | 8 | 2024 | 13490 | 0.620 |
Why?
|
Lymph Node Excision | 10 | 2023 | 1271 | 0.620 |
Why?
|
Lymphatic Metastasis | 8 | 2024 | 2914 | 0.590 |
Why?
|
Breast | 7 | 2024 | 1976 | 0.570 |
Why?
|
Lymphedema | 1 | 2023 | 527 | 0.550 |
Why?
|
Nipples | 3 | 2020 | 227 | 0.510 |
Why?
|
Neoadjuvant Therapy | 10 | 2023 | 2907 | 0.500 |
Why?
|
Paget's Disease, Mammary | 2 | 2013 | 18 | 0.500 |
Why?
|
Pregnancy Complications, Neoplastic | 3 | 2016 | 260 | 0.490 |
Why?
|
Genes, erbB-2 | 2 | 2019 | 162 | 0.490 |
Why?
|
Carcinoma | 2 | 2021 | 2332 | 0.400 |
Why?
|
Arm | 3 | 2024 | 591 | 0.400 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2024 | 9419 | 0.360 |
Why?
|
Breast Diseases | 2 | 2013 | 442 | 0.350 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2019 | 1099 | 0.350 |
Why?
|
Decision Support Techniques | 2 | 2021 | 2008 | 0.340 |
Why?
|
Hyperplasia | 1 | 2012 | 1151 | 0.320 |
Why?
|
Female | 66 | 2025 | 397192 | 0.320 |
Why?
|
Carcinoma, Lobular | 3 | 2019 | 480 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 11878 | 0.300 |
Why?
|
Receptors, Estrogen | 6 | 2025 | 2253 | 0.290 |
Why?
|
Neoplasm, Residual | 4 | 2022 | 1015 | 0.280 |
Why?
|
Pain, Postoperative | 6 | 2022 | 1765 | 0.270 |
Why?
|
Reoperation | 1 | 2017 | 4329 | 0.270 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2019 | 150 | 0.270 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2021 | 1791 | 0.250 |
Why?
|
Receptor, erbB-2 | 6 | 2025 | 2603 | 0.250 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2022 | 3556 | 0.230 |
Why?
|
Radiosurgery | 2 | 2024 | 1330 | 0.230 |
Why?
|
Humans | 71 | 2025 | 768166 | 0.230 |
Why?
|
Prognosis | 14 | 2025 | 30010 | 0.200 |
Why?
|
Breast Neoplasms, Male | 2 | 2021 | 213 | 0.180 |
Why?
|
Postoperative Complications | 6 | 2020 | 15832 | 0.180 |
Why?
|
Decision Making | 4 | 2022 | 3953 | 0.180 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 934 | 0.180 |
Why?
|
Receptors, Progesterone | 4 | 2025 | 1160 | 0.180 |
Why?
|
Aged | 24 | 2024 | 171504 | 0.170 |
Why?
|
Adult | 29 | 2024 | 223646 | 0.170 |
Why?
|
Prospective Studies | 16 | 2024 | 54926 | 0.160 |
Why?
|
Patient Satisfaction | 3 | 2021 | 3488 | 0.160 |
Why?
|
Breast Implants | 2 | 2020 | 414 | 0.160 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26379 | 0.150 |
Why?
|
Combined Modality Therapy | 5 | 2019 | 8542 | 0.150 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39348 | 0.140 |
Why?
|
Middle Aged | 23 | 2025 | 223492 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 788 | 0.140 |
Why?
|
Neoplasm Invasiveness | 5 | 2019 | 3620 | 0.130 |
Why?
|
Certification | 1 | 2019 | 420 | 0.130 |
Why?
|
Anesthesia, Conduction | 1 | 2019 | 263 | 0.130 |
Why?
|
Retrospective Studies | 16 | 2023 | 81762 | 0.130 |
Why?
|
Catastrophization | 1 | 2019 | 352 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 798 | 0.120 |
Why?
|
Aged, 80 and over | 12 | 2024 | 59629 | 0.110 |
Why?
|
Genes, BRCA2 | 1 | 2017 | 593 | 0.110 |
Why?
|
Education, Medical, Continuing | 1 | 2019 | 829 | 0.110 |
Why?
|
Patient Care | 1 | 2019 | 629 | 0.110 |
Why?
|
Young Adult | 10 | 2021 | 60066 | 0.110 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 755 | 0.110 |
Why?
|
Patient Education as Topic | 2 | 2024 | 2337 | 0.110 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9263 | 0.110 |
Why?
|
Patient Participation | 1 | 2022 | 1447 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 952 | 0.100 |
Why?
|
Age Factors | 5 | 2021 | 18412 | 0.100 |
Why?
|
Time Factors | 4 | 2024 | 40218 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2020 | 1384 | 0.100 |
Why?
|
Survival Rate | 5 | 2025 | 12840 | 0.100 |
Why?
|
Antineoplastic Agents | 2 | 2013 | 13676 | 0.100 |
Why?
|
Mammography | 2 | 2013 | 2433 | 0.090 |
Why?
|
Radiotherapy | 1 | 2018 | 1502 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2022 | 1885 | 0.090 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7454 | 0.090 |
Why?
|
Ethics, Medical | 1 | 2015 | 785 | 0.090 |
Why?
|
Psychometrics | 1 | 2020 | 3063 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2665 | 0.080 |
Why?
|
Intraoperative Care | 1 | 2013 | 770 | 0.080 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2227 | 0.080 |
Why?
|
Treatment Outcome | 9 | 2021 | 65371 | 0.080 |
Why?
|
Radiographic Image Enhancement | 1 | 2013 | 877 | 0.080 |
Why?
|
Thyroid Neoplasms | 1 | 2022 | 2360 | 0.080 |
Why?
|
Sample Size | 1 | 2011 | 846 | 0.080 |
Why?
|
Guideline Adherence | 1 | 2018 | 2235 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4362 | 0.070 |
Why?
|
Cellulitis | 1 | 2010 | 206 | 0.070 |
Why?
|
Qualitative Research | 1 | 2019 | 3140 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7852 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3415 | 0.070 |
Why?
|
Consensus | 1 | 2016 | 3212 | 0.070 |
Why?
|
Abscess | 1 | 2010 | 606 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6847 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1883 | 0.060 |
Why?
|
Postmenopause | 2 | 2024 | 2518 | 0.060 |
Why?
|
Body Image | 2 | 2020 | 646 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3436 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2022 | 4887 | 0.060 |
Why?
|
Hematoma | 1 | 2010 | 766 | 0.060 |
Why?
|
Fluorouracil | 1 | 2010 | 1652 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4055 | 0.060 |
Why?
|
Massachusetts | 2 | 2021 | 8890 | 0.060 |
Why?
|
Models, Statistical | 1 | 2018 | 5107 | 0.050 |
Why?
|
Risk Assessment | 2 | 2018 | 24315 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8054 | 0.050 |
Why?
|
Clinical Competence | 1 | 2019 | 4858 | 0.050 |
Why?
|
Angiogenesis Inhibitors | 1 | 2013 | 2056 | 0.050 |
Why?
|
Doxorubicin | 1 | 2010 | 2234 | 0.050 |
Why?
|
Postpartum Period | 1 | 2010 | 1198 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13586 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5520 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12543 | 0.050 |
Why?
|
Ketoprofen | 1 | 2000 | 8 | 0.050 |
Why?
|
Sudden Infant Death | 1 | 2003 | 293 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 6526 | 0.040 |
Why?
|
Pain Measurement | 3 | 2019 | 3583 | 0.040 |
Why?
|
Analgesia, Patient-Controlled | 1 | 2000 | 117 | 0.040 |
Why?
|
Biopsy | 1 | 2011 | 6793 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10399 | 0.040 |
Why?
|
Surgical Instruments | 1 | 2022 | 381 | 0.040 |
Why?
|
Physicians | 2 | 2015 | 4598 | 0.040 |
Why?
|
Comprehension | 1 | 2024 | 638 | 0.040 |
Why?
|
Serotonin | 1 | 2003 | 1043 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 466 | 0.040 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2023 | 452 | 0.040 |
Why?
|
Brain Stem | 1 | 2003 | 859 | 0.040 |
Why?
|
Mind-Body Therapies | 1 | 2021 | 294 | 0.040 |
Why?
|
Iodine Radioisotopes | 1 | 2022 | 1034 | 0.040 |
Why?
|
Pregnancy | 4 | 2016 | 30256 | 0.030 |
Why?
|
Anxiety | 2 | 2022 | 4672 | 0.030 |
Why?
|
Preoperative Period | 1 | 2018 | 565 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 13014 | 0.030 |
Why?
|
Morphine | 1 | 2000 | 658 | 0.030 |
Why?
|
Benchmarking | 1 | 2022 | 1057 | 0.030 |
Why?
|
Disease Management | 2 | 2018 | 2536 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1755 | 0.030 |
Why?
|
Paclitaxel | 1 | 2023 | 1733 | 0.030 |
Why?
|
Health Plan Implementation | 1 | 2018 | 338 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2011 | 22291 | 0.030 |
Why?
|
Anthracyclines | 1 | 2017 | 286 | 0.030 |
Why?
|
United States | 4 | 2023 | 73039 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8375 | 0.030 |
Why?
|
Taxoids | 1 | 2017 | 667 | 0.030 |
Why?
|
Methylene Blue | 1 | 2014 | 156 | 0.030 |
Why?
|
Exercise | 2 | 2021 | 5955 | 0.030 |
Why?
|
Hormones | 1 | 2017 | 866 | 0.030 |
Why?
|
Data Collection | 1 | 2022 | 3327 | 0.030 |
Why?
|
Analgesics, Opioid | 2 | 2018 | 3837 | 0.030 |
Why?
|
Republic of Korea | 1 | 2015 | 591 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 1078 | 0.020 |
Why?
|
Exercise Therapy | 1 | 2019 | 939 | 0.020 |
Why?
|
Depression | 2 | 2022 | 8230 | 0.020 |
Why?
|
Coloring Agents | 1 | 2014 | 565 | 0.020 |
Why?
|
Dermis | 1 | 2013 | 203 | 0.020 |
Why?
|
Algorithms | 1 | 2011 | 14164 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 2271 | 0.020 |
Why?
|
Neoplasms | 1 | 2019 | 22371 | 0.020 |
Why?
|
Orthopedic Procedures | 1 | 2000 | 1279 | 0.020 |
Why?
|
Preoperative Care | 1 | 2019 | 2258 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1641 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4260 | 0.020 |
Why?
|
Ultrasonography | 1 | 2022 | 6004 | 0.020 |
Why?
|
Risk Factors | 2 | 2018 | 74944 | 0.020 |
Why?
|
Patient Readmission | 1 | 2023 | 3288 | 0.020 |
Why?
|
Efficiency, Organizational | 1 | 2013 | 697 | 0.020 |
Why?
|
Gestational Age | 1 | 2016 | 3621 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2022 | 4530 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3467 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8741 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2022 | 14783 | 0.020 |
Why?
|
Cohort Studies | 2 | 2020 | 41754 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2022 | 26422 | 0.020 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5432 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6809 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2024 | 6974 | 0.010 |
Why?
|
Lysergic Acid Diethylamide | 1 | 2003 | 49 | 0.010 |
Why?
|
Infant | 2 | 2022 | 36535 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10474 | 0.010 |
Why?
|
Hospitalization | 1 | 2023 | 10840 | 0.010 |
Why?
|
Autoradiography | 1 | 2003 | 727 | 0.010 |
Why?
|
Receptors, Serotonin | 1 | 2003 | 211 | 0.010 |
Why?
|
Adolescent | 3 | 2019 | 89169 | 0.010 |
Why?
|
Smoke | 1 | 2003 | 242 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2020 | 20227 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15948 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2013 | 3269 | 0.010 |
Why?
|
Indians, North American | 1 | 2003 | 354 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2013 | 3929 | 0.010 |
Why?
|
Male | 4 | 2024 | 364719 | 0.010 |
Why?
|
Skin | 1 | 2013 | 4503 | 0.010 |
Why?
|
Ethanol | 1 | 2003 | 1331 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2003 | 2741 | 0.010 |
Why?
|
Placebos | 1 | 2000 | 1667 | 0.010 |
Why?
|
Binding Sites | 1 | 2003 | 6020 | 0.010 |
Why?
|
Drug Combinations | 1 | 2000 | 2089 | 0.010 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2003 | 2538 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2000 | 12465 | 0.000 |
Why?
|
Concepts
(202)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(75)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_